- recruiting
PROCARE - PROstate Cancer Real World Evidence Registry
This study is gathering information on men with prostate cancer that has come back or spread. It looks at how their condition progresses and how treatments work in real life. It aims to help us understand the best ways to manage different stages of prostate cancer.
Germany - recruitingPhase III
A phase 3 randomized double-blinded, placebo-controlled study of JNJ-78278343, T-Cell redirecting agent targeting Human Kallikrein 2 with best supportive care (BSC) versus placebo with BSC for metastatic castration-resistant prostate cancer_KLK2 comPAS_78278343PCR3001
This study is testing a new drug called pasritamig for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. It aims to see if pasritamig, along with usual care, helps men live longer compared to a dummy drug.
United Kingdom · England · Northern Ireland - active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
This study looks at a new drug, BMS-986365, for men with prostate cancer that has spread and is no longer responding to hormone treatment. We want to see if it works better and is safer than standard treatments chosen by doctors.
United States · Argentina · Australia - recruitingPHASE3
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
This study is looking into a new drug, PF-06821497, combined with an existing drug, enzalutamide, for men with advanced prostate cancer. It wants to see if this combination works better than enzalutamide alone for those who haven't had certain other treatments.
United States · Argentina · Brazil - ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide Compared with Enzalutamide Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new drug, EPI-7386, combined with an existing prostate cancer drug, Xtandi. It's for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. Researchers want to see if this combination is safe and if it helps shrink the cancer.
Spain · Belgium · France - active not recruitingPHASE3
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
This study is looking at a new medicine called Xaluritamig for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It compares Xaluritamig to existing treatments like Cabazitaxel or other hormone therapies, to see which is more effective at helping men live longer.
United States · Australia · Austria - active not recruitingPHASE1, PHASE2
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
This study is looking at new ways to treat advanced prostate cancer that has spread and medicines like hormone therapy no longer work. Researchers are testing the drug pembrolizumab, sometimes with other treatments, to see if it's safe and effective, aiming to find better options for patients.
United States · Denmark · France - recruitingPHASE1, PHASE2
ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
This study is testing a new radioactive drug called Actinium (225Ac) rhPSMA-10.1 for men with advanced prostate cancer that has spread. It aims to find a safe dose and see how well it works, especially for those who've already had a similar treatment.
United Kingdom - recruitingPHASE3
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
This study is testing a new drug, AZD2265, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. We want to see if AZD2265 works better than current treatments at slowing down cancer growth and helping men live longer.
United States · Australia · Austria - recruitingPHASE1
A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study
This study looks at a new drug, AAA617, for men with advanced prostate cancer that has spread. We want to find the safest dose, check for side effects, and see how well it works when given for a longer time.
United States · Germany · Netherlands - recruitingPHASE1
A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer
This study is testing a new drug, DS9051b, for people with advanced adrenal gland cancer or prostate cancer that has spread. Researchers want to see if it's safe, how much to give, and if it shows early signs of working.
United States · France · United Kingdom - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)
This study is looking at a new medicine called MGC018 (also known as vobramitamab duocarmazine) for men with prostate cancer that has spread and is no longer responding to standard hormone therapy. Researchers want to see how well it works and if it's safe at two different dose levels.
Belgium · Germany · France - ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
SAFETY AND PHARMACOKINETICS OF ODM-208 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
This study looks at a new drug, ODM-208, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It checks if the drug is safe, what dose works best, and how it moves through the body.
France · Finland - active not recruitingPHASE1
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new prostate cancer drug, JNJ-56021927, alongside existing treatments like abiraterone acetate and prednisone. Researchers want to see if these drugs work well together, check for side effects, and find the best doses for future studies in men with advanced prostate cancer.
United States · Canada · Netherlands - active not recruitingPHASE1
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
This study looks at a new drug called XL092 for advanced solid tumours like kidney, breast, prostate, or bowel cancer. Researchers are testing it alone and with other drugs (Atezolizumab, Avelumab) to see if it's safe, how it works, and if it can help slow down or shrink tumours.
United States · Australia · Belgium - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of JNJ-70218902, a T Cell Redirecting Agent, in Advanced Stage Solid Tumors
This early-stage study is testing a new drug, JNJ-70218902, for men with advanced prostate cancer that has spread and no longer responds to standard hormone treatments. It aims to see if the drug is safe and how it works in the body.
Spain - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer
This study looks at new drug combinations for men with advanced prostate cancer that has stopped responding to hormone therapy. It compares different treatments to see which works best at shrinking tumours and slowing cancer growth.
Germany - recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - recruitingPHASE2
A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, Inavolisib, combined with Enzalutamide for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to other standard treatments.
United States · Australia · Brazil - recruitingPHASE2
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
This study looks at a new injection, ASP5541, for advanced prostate cancer that has spread. It compares ASP5541 to a standard tablet treatment, abiraterone acetate, to see how safe and effective it is.
United States · China · France - recruitingPHASE3
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
This study is looking at a new treatment, Xaluritamig, combined with Abiraterone, for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It compares this combination to standard treatments to see if it helps men live longer.
United States · Australia · Austria - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Open-Label, Study of Lorigerlimab with Docetaxel or Docetaxel Alone in Participants with Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new drug called Lorigerlimab, given with or without standard chemotherapy (docetaxel), for men with prostate cancer that has spread and is resistant to hormone treatment. The main goal is to see if Lorigerlimab can help men live longer without their cancer getting worse.
Spain · Poland · Belgium - recruitingPHASE3
A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer
This study is for men with advanced prostate cancer that has spread and stopped responding to hormone treatment. It compares a new medicine, BNT324, with standard chemotherapy (docetaxel) to see if BNT324 can help patients live longer and keep their cancer from growing for longer.
United States · China · United Kingdom - active not recruitingPHASE3
Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer
This study looks at a new combination treatment for advanced prostate cancer that has spread. It compares olaparib plus abiraterone with abiraterone alone to see if the new combination works better and is safe for men who haven't had previous strong treatments.
United States · Australia · Belgium - recruitingPHASE1, PHASE2
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
This study is testing a new medicine, Tulmimetostat, for people with advanced cancers like solid tumours and lymphomas. It's looking at how safe it is, any side effects, and if it helps to shrink tumours.
United States · France · Italy - ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)
This study looks at a new drug, pembrolizumab (Keytruda), combined with another medicine, enzalutamide. It's for men with advanced prostate cancer that has spread and isn't responding to hormone treatment. We want to see if this combination helps men live longer and slows down the cancer's growth.
Austria · Italy · Netherlands - active not recruitingPHASE1
[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer
This study is testing a new treatment, [Ac-225]-PSMA-62, for advanced prostate cancer. It aims to find the safest and most effective dose, and see how well it works in men whose cancer has spread or returned.
Canada - recruiting
Real-World Clinical Experience of Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Olaparib + Abiraterone (PROceed)
This study looks at how a combination of two medicines, olaparib and abiraterone, works for men with advanced prostate cancer that has stopped responding to hormone therapy. It aims to understand how these men get on in real life, outside of a strict clinical trial.
Germany - active not recruitingPHASE3
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment
This study looks at a new treatment, [Lu-177]-PNT2002, for advanced prostate cancer that has spread and isn't responding to standard hormone therapy. It compares this new treatment with existing hormone therapies to see if it can slow down cancer growth.
United States · Canada · France - active not recruitingPHASE1
A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is testing a new treatment, BAY3546828, for advanced prostate cancer that has spread and no longer responds to hormone therapy. Researchers want to find a safe and effective dose, understand how it works in the body, and see if it can shrink tumours.
United States · Canada · Finland - recruitingPHASE1, PHASE2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
This study is testing a new treatment for advanced prostate cancer that has spread and isn't responding to usual hormone therapy. It's called 177Lu-rhPSMA-10.1 and uses radiation to target cancer cells. We want to see how safe and effective it is.
United States · Belgium · Germany - recruitingPHASE3
The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)
This study looks at a new drug, 177Lu-TLX591, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It compares this new drug combined with standard treatments to standard treatments alone.
United States · Australia · Canada - enrolling by invitationPHASE1, PHASE2
177Lu-HTK03170 in mCRPC With PSMA Positive Disease
This study is for men with advanced prostate cancer that has spread and is no longer responding to standard hormone therapy. It tests a new radioactive drug called 177Lu-HTK03170 to find the safest dose and see if it can shrink the cancer.
Canada